Clinical Trials on Recurrent Verrucous Carcinoma of the Oral Cavity

Total 1863 results

Instituto do Cancer do Estado de São Paulo
Instituto de Ciências Biomédicas da Universidade de São Paulo

Not yet recruiting

Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population (ALDH2020)

Oral Squamous Cell Carcinoma (OSCC)

Brazil
Academy of Interdisciplinary Dental Education and...
Postgraduate Medical Institute, Lahore

Unknown

Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma (OSCC)

Oral Squamous Cell Carcinoma | Oral Epithelial Dysplasia

Pakistan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Pancreatic Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Malignant Neoplasm | Recurrent Colorectal Carcinoma | Pancreatic Neuroendocrine Carcinoma | Malignant Head and Neck Neoplasm | Stage III Nasopharyngeal Carcinoma... and other conditions

United States
NATCO Pharma Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Carcinoma | Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

United States, India
SWOG Cancer Research Network
National Cancer Institute (NCI)

Terminated

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Recurrent Lung Adenocarcinoma | Stage IV Lung Adenocarcinoma | Recurrent Large Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma | Stage IV Large Cell Lung Carcinoma

United States, Mexico
National Cancer Institute (NCI)

Terminated

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Locally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell Carcinoma

United States
Tarveda Therapeutics

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

Neoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditions

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Patients With Stage IV or Recurrent Adenocarcinoma of the Lung
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer

Colorectal Cancer | Primary Peritoneal Cavity Cancer | Carcinoma of the Appendix

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Suitability of DCE-MRI for Detection of Vascular Changes After VBT

Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC; Joseph Sanchez Foundation

Active, not recruiting

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center

Withdrawn

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell Carcinoma
Bengtson Center
Allergan Medical

Completed

Seri Surgical Scaffold Support of the Lower Pole of the Breast (SeriSupport)

Recurrent Ptosis of the Breast

United States
University of Leipzig
University of Kiel; University of Cologne; University of Jena; Technical University... and other collaborators

Not yet recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (ELOS)

Laryngeal Cancer | Squamous Cell Carcinoma of Head and Neck | Laryngeal Neoplasms | Squamous Cell Carcinoma of the Larynx | Hypopharyngeal Squamous Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Laryngectomy; Status | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of the Larynx Stage... and other conditions
University of Sao Paulo

Completed

Visual Performance of New Apodized Diffractive Multifocal IOL With Addition of Plus Three

To Study the Influence of an Multifocal Intraocular Lens With Different Addition on Intermediate Visual Acuity

Brazil
Merck KGaA, Darmstadt, Germany

Completed

Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Carcinoma of the Head and Neck

Japan
Rambam Health Care Campus

Unknown

Fungal Infection After Oral Cavity Surgeries

Prevalence of Fungal Infection in Patients Undergoing Oral Cavity Surgery Without Treatment With Antifungal Drug
Trakya University

Active, not recruiting

Surgical Management of Stage-2 MRONJ With Transplantation of HAM

Oral Surgery | Medication Related Osteonecrosis of the Jaw

Turkey
Nektar Therapeutics
Merck Sharp & Dohme LLC; SFJ Pharmaceuticals, Inc.

Terminated

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer

United States, Austria, Greece, Italy
Universitätsklinikum Hamburg-Eppendorf

Completed

Esophagogastrectomy Versus Extended Gastrectomy in AEG II (AEG-II-EG)

Carcinomas of the Esophagogastric Junction

Germany
National Cancer Institute (NCI)

Completed

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Glenn J. Hanna
ImmunityBio, Inc.

Recruiting

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
Hospital Donostia

Recruiting

Magnetic Localization of Sentinel Nodes in Squamous Cell Oral Carcinoma. (SentiMag)

Diagnostic Value of Sentinel Node Biopsy Guided by Magnetic Probe

Spain
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, Canada, United Kingdom
M.D. Anderson Cancer Center

Recruiting

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
University College, London
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United Kingdom
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Trisha Wise-Draper
AstraZeneca

Active, not recruiting

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Metastatic Cancer | Recurrent Head and Neck Cancer

United States
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (APA)

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and Neck

United States
University of Chicago
National Cancer Institute (NCI)

Terminated

Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer

Tongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx

United States
The University of Hong Kong

Completed

Effectiveness of Different Incentive Models in Booster up the Second Follow up Response Rate

To Test the Effectiveness of Different Incentive Models for Increasing the Follow-up Response Rate in the Current Smoker Subject

Hong Kong
Erasmus Medical Center

Not yet recruiting

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial (STELLAR)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Hypopharynx

Netherlands
University of Birmingham
AstraZeneca; Cancer Research UK

Completed

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer (WISTERIA)

Larynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Patients With Head and Neck Cancer. (ProNiHN)

Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

France
National University Hospital, Singapore

Unknown

Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Lung

Singapore
University of Southern California
Sanofi

Terminated

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

Carcinoma of the Head and Neck

United States
Western Regional Medical Center

Terminated

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

Adenocarcinoma of the Cervix | Adenosquamous Cell Carcinoma of the Cervix

United States
Danish Head and Neck Cancer Group

Completed

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Cancer of the Head and Neck

Denmark
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Accelerated Community Oncology Research Network
Amgen

Terminated

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal Stomach

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Replimune Inc.
Bristol-Myers Squibb

Withdrawn

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Squamous Cell Carcinoma of Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma

United States, Spain, United Kingdom, Czechia, France, Germany, Greece, Poland
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Recurrent Gastric Carcinoma | Esophageal Undifferentiated Carcinoma | Gastric Squamous Cell Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IV Esophageal Adenocarcinoma | Stage... and other conditions

United States
Sheba Medical Center

Not yet recruiting

Vitamin A for BPD Prevention

The Relationship Between Oral Vitamin A Administration and the Incidence of BPD in Preterm Infants Born Before Week 29 of Pregnancy
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
Weill Medical College of Cornell University
Sanofi

Withdrawn

Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer

Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
National Cancer Institute (NCI)

Completed

S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer

Stage IV Gastric Cancer | Recurrent Gastric Cancer | Stage III Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach

United States

Clinical Trials on Recurrent Verrucous Carcinoma of the Oral Cavity

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations